China SXT Pharmaceuticals (SXTC) Equity Ratio (2018 - 2025)
Historic Equity Ratio for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q1 2025 value amounting to 0.71.
- China SXT Pharmaceuticals' Equity Ratio rose 1832.25% to 0.71 in Q1 2025 from the same period last year, while for Mar 2025 it was 0.71, marking a year-over-year increase of 1832.25%. This contributed to the annual value of 0.71 for FY2025, which is 1832.25% up from last year.
- China SXT Pharmaceuticals' Equity Ratio amounted to 0.71 in Q1 2025, which was up 1832.25% from 0.6 recorded in Q1 2024.
- China SXT Pharmaceuticals' Equity Ratio's 5-year high stood at 0.71 during Q1 2025, with a 5-year trough of 0.46 in Q1 2021.
- Its 5-year average for Equity Ratio is 0.55, with a median of 0.5 in 2023.
- Per our database at Business Quant, China SXT Pharmaceuticals' Equity Ratio surged by 152.89% in 2023 and then soared by 2117.18% in 2024.
- China SXT Pharmaceuticals' Equity Ratio (Quarter) stood at 0.46 in 2021, then increased by 5.97% to 0.49 in 2022, then rose by 1.53% to 0.5 in 2023, then increased by 21.17% to 0.6 in 2024, then rose by 18.32% to 0.71 in 2025.
- Its last three reported values are 0.71 in Q1 2025, 0.6 for Q1 2024, and 0.5 during Q1 2023.